Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Importance: Mood stabilizers and antipsychotics are the main maintenance treatments for bipolar disorder. Lithium is considered to be the most effective mood stabilizer, but very little is known about overall health outcomes associated with specific treatments and the comparative long-term effectiveness of specific psychotropics or routes of administration in the prevention of rehospitalizations. Objective: To study the comparative effectiveness of pharmacologic treatments in the prevention of rehospitalization in a nationwide cohort of patients with bipolar disorder. Design, Setting, and Participants: This cohort study examined the risk of psychiatric, cardiovascular, and all-cause hospitalization from January 1, 1987, to December 31, 2012, among all patients in Finland who had been hospitalized for bipolar disorder (N = 18 018; mean follow-up time, 7.2 years) using prospectively gathered nationwide databases for hospitalization and dispensed medications. The primary analysis was within-individual analysis, in which each individual was used as his or her own control to eliminate selection bias. The study adjusted for the effect of concomitant psychotropic medications, duration of illness, and the temporal orders of exposure and nonexposure periods. Statistical analysis was conducted from January 1, 1996, to December 31, 2012. Main Outcomes and Measures: Adjusted hazard ratios (HRs) for rehospitalization were calculated. Results: Among the cohort (9558 women and 8460 men; mean [SD] age, 46.6 [17.0] years), 9721 patients (54.0%) had at least 1 psychiatric rehospitalization. In comparison between use and no use among specific agents reaching nominal statistical significance, risperidone long-acting injection (HR, 0.58 [95% CI, 0.34-1.00]), gabapentin (HR, 0.58 [95% CI, 0.44-0.77]), perphenazine long-acting injection (HR, 0.60 [95% CI, 0.41-0.88]), and lithium carbonate (HR, 0.67 [95% CI, 0.60-0.73]) were associated with the lowest risk of psychiatric rehospitalization. Concerning all-cause hospitalization, lithium (HR, 0.71 [95% CI, 0.66-0.76]) was associated with the lowest risk. The most frequently used antipsychotic treatment, quetiapine fumarate, showed only modest effectiveness (risk of psychiatric rehospitalization: HR, 0.92 [95% CI, 0.85-0.98]; risk of all-cause hospitalization: HR, 0.93 [95% CI, 0.88-0.98]). Long-acting injections were associated with substantially better outcomes compared with identical oral antipsychotics (risk of psychiatric rehospitalization: HR, 0.70 [95% CI, 0.55-0.90]; risk of all-cause hospitalization: HR, 0.70 [95% CI, 0.57-0.86]). Results from sensitivity analyses showed consistent beneficial effects only for lithium and for long-acting injections compared with their oral counterparts. Conclusions and Relevance: Lithium was the most effective mood stabilizer, and long-acting injections the most effective antipsychotics, in preventing hospitalization due to mental or physical illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Self-citationMiura, T., Noma, H., Furukawa, T. A., Mitsuyasu, H., Tanaka, S., Stockton, S., Salanti, G., Motomura, K., Shimano-Katsuki, S., Leucht, S., et al. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70314-1 · Cited by 364
Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies
Markota, M., Rummans, T. A., Bostwick, J. M., & Lapid, M. I. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.07.024 · Cited by 307
Song, J., Sjölander, A., Joas, E., Bergen, S. E., Runeson, B., Larsson, H., Landén, M., & Lichtenstein, P. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16050542 · Cited by 147 · cited 1×
“Joasetal16 suggested that lithium is more effective than both quetiapine and olanzapine in prevention of relapse in bipolar disorder, and a study by Song et al17 suggested that lithium is superior to valproate sodium in preventing suicidal behavior in bipolar patients.”
BackgroundPrescribed Benzodiazepines and Suicide Risk: A Review of the Literature
Dodds, T. J. (2017) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.16r02037 · Cited by 144
Vieta, E., Montgomery, S., Sulaiman, A. H., Cordoba, R., Huberlant, B., Martinez, L., & Schreiner, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.004 · Cited by 130
Self-citationHayes, J. F., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. J. (2016) · World Psychiatry · doi:10.1002/wps.20298 · Cited by 115
Kessing, L. V., Hellmund, G., Geddes, J. R., Goodwin, G. M., & Andersen, P. K. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084822 · Cited by 105
Bonnín, C. D. M., González-Pinto, A., Solé, B., Reinares, M., González-Ortega, I., Alberich, S., Crespo, J. M., Salamero, M., Vieta, E., Martínez-Arán, A., et al. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.034 · Cited by 76
Self-citationTiihonen, J., Tanskanen, A., Hoti, F., Vattulainen, P., Taipale, H., Mehtälä, J., & Lähteenvuo, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30134-7 · Cited by 58 · cited 1×
“Longtermmedication is often required to attain remission and prevent relapses, although, evenwith advanced treatment protocols, rates of remission remain low.(3)Many randomizedclinical trials and their meta-analyses have been performed to discover themostefficacious treatment formsforpreventionof relapse; somemore rec…”
BackgroundSelf-citationThe course of bipolar disorder
Saunders, K. E. A., & Goodwin, G. M. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.004903 · Cited by 56
Cited by
McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationKishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00946-6 · Cited by 169
Shulman, K. I., Almeida, O. P., Herrmann, N., Schaffer, A., Strejilevich, S. A., Paternoster, C., Amodeo, S., Dols, A., & Sajatovic, M. (2019) · Bipolar Disorders · doi:10.1111/bdi.12714 · Cited by 86
Hafeman, D. M., Rooks, B., Merranko, J., Liao, F., Gill, M. K., Goldstein, T. R., Diler, R., Ryan, N., Goldstein, B. I., Axelson, D. A., et al. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.06.013 · Cited by 83
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Self-citation
Metadata
- Authors
- Lähteenvuo, M., Tanskanen, A., Taipale, H., Hoti, F., Vattulainen, P., Vieta, E., & Tiihonen, J.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2018-04-01
- Volume
- 75
- Issue
- 4
- Pages
- 347
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2792416293
- Cited by
- 156
- References
- 14
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.